|
1
|
Lee JM, Ivy SP and Kohn EC: Challenges and
opportunities for immunotherapies in gynecologic cancers. Oncology
(Williston Park). 30:67–69. 2016.PubMed/NCBI
|
|
2
|
Bourla AB and Zamarin D: Immunotherapy:
New strategies for the treatment of gynecologic malignancies.
Oncology (Williston Park). 30:59–66, 69. 2016.PubMed/NCBI
|
|
3
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Whole-genome characterization of chemoresistant ovarian
cancer. Nature. 521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Strickland KC, Howitt BE, Shukla SA, Rodig
S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea
AD, et al: Association and prognostic significance of
BRCA1/2-mutation status with neoantigen load, number of
tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high
grade serous ovarian cancer. Oncotarget. 7:13587–13598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sucheston-Campbell LE, Cannioto R, Clay
AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB,
Minlikeeva A, et al: No evidence that genetic variation in the
myeloid-derived suppressor cell pathway influences ovarian cancer
survival. Cancer Epidemiol Biomarkers Prev. 26:420–424. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Barnett BG, Rüter J, Kryczek I, Brumlik
MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W and Curiel TJ: Regulatory
T cells: A new frontier in cancer immunotherapy. Adv Exp Med Biol.
622:255–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu L, Deng Z, Peng Y, Han L, Liu J, Wang
L, Li B, Zhao J, Jiao S and Wei H: Ascites-derived IL-6 and IL-10
synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor
cells in ovarian cancer patients. Oncotarget. 8:76843–76856.
2017.PubMed/NCBI
|
|
13
|
Candido-dos-Reis FJ, Song H, Goode EL,
Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington
P, Ramus SJ, et al: Germline mutation in BRCA1 or BRCA2 and
ten-year survival for women diagnosed with epithelial ovarian
cancer. Clin Cancer Res. 21:652–657. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi L, Li B, Dong Y, Xu H, Chen L, Wang H,
Li P, Zhao W, Gu Y, Wang C and Guo Z: Deconvolution of the gene
expression profiles of valuable banked blood specimens for studying
the prognostic values of altered peripheral immune cell proportions
in cancer patients. PLoS One. 9:e1009342014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Showe MK, Kossenkov AV and Showe LC: The
peripheral immune response and lung cancer prognosis.
OncoImmunology. 1:1414–1416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarraf KM, Belcher E, Raevsky E, Nicholson
AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its
association with survival after complete resection in non-small
cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JM, Hays JL, Annunziata CM, Noonan AM,
Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al:
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2
mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. 106:dju0892014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JM, Peer CJ, Yu M, Amable L, Gordon N,
Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, et al:
Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib
study of olaparib tablets and carboplatin in women's cancer. Clin
Cancer Res. 23:1397–1406. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomas A, Rajan A, Szabo E, Tomita Y,
Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A,
et al: A phase I/II trial of belinostat in combination with
cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial
tumors: A clinical and translational study. Clin Cancer Res.
20:5392–5402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoppenot C, Eckert MA, Tienda SM and
Lengyel E: Who are the long-term survivors of high grade serous
ovarian cancer? Gynecol Oncol. 148:204–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nelson BH: The impact of T-cell immunity
on ovarian cancer outcomes. Immunol Rev. 222:101–116. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McAlpine JN, Porter H, Kobel M, Nelson BH,
Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, et al:
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and
presence of immune cell infiltrates in ovarian high-grade serous
carcinoma. Mod Pathol. 25:740–750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang WT, Adams SF, Tahirovic E, Hagemann
IS and Coukos G: Prognostic significance of tumor-infiltrating T
cells in ovarian cancer: A meta-analysis. Gynecol Oncol.
124:192–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yigit R, Massuger LF, Figdor CG and
Torensma R: Ovarian cancer creates a suppressive microenvironment
to escape immune elimination. Gynecol Oncol. 117:366–372. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Movahedi K, Guilliams M, Van den Bossche
J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P and Van
Ginderachter JA: Identification of discrete tumor-induced
myeloid-derived suppressor cell subpopulations with distinct T
cell-suppressive activity. Blood. 111:4233–4244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang R, Cai Z, Zhang Y, Yutzy WH IV, Roby
KF and Roden RB: CD80 in immune suppression by mouse ovarian
carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res.
66:6807–6815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Diaz-Montero CM, Salem ML, Nishimura MI,
Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating
myeloid-derived suppressor cells correlate with clinical cancer
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide
chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen J, Ye Y, Liu P, Yu W, Wei F, Li H and
Yu J: Suppression of T cells by myeloid-derived suppressor cells in
cancer. Hum Immunol. 78:113–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick
R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al:
Myeloid-derived suppressor cells enhance stemness of cancer cells
by inducing microRNA101 and suppressing the corepressor CtBP2.
Immunity. 39:611–621. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higuchi T, Flies DB, Marjon NA,
Mantia-Smaldone G, Ronner L, Gimotty PA and Adams SF: CTLA-4
blockade synergizes therapeutically with PARP inhibition in
BRCA1-deficient ovarian cancer. Cancer Immunol Res. 3:1257–1268.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Buckley NE, Hosey AM, Gorski JJ, Purcell
JW, Mulligan JM, Harkin DP and Mullan PB: BRCA1 regulates IFN-gamma
signaling through a mechanism involving the type I IFNs. Mol Cancer
Res. 5:261–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu H, Xian J, Vire E, McKinney S, Wei V,
Wong J, Tong R, Kouzarides T, Caldas C and Aparicio S:
Up-regulation of the interferon-related genes in BRCA2 knockout
epithelial cells. J Pathol. 234:386–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T,
Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, et al: PARP inhibition
elicits STING-dependent antitumor immunity in brca1-deficient
ovarian cancer. Cell Rep. 25:2972–2980.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ghaffari A, Peterson N, Khalaj K, Vitkin
N, Robinson A, Francis JA and Koti M: STING agonist therapy in
combination with PD-1 immune checkpoint blockade enhances response
to carboplatin chemotherapy in high-grade serous ovarian cancer. Br
J Cancer. 119:440–449. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nguyen LT and Ohashi PS: Clinical blockade
of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol.
15:45–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Keir ME, Francisco LM and Sharpe AH: PD-1
and its ligands in T-cell immunity. Curr Opin Immunol. 19:309–314.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:3360–3365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu J, Liu C, Qian S and Hou H: The
expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell
Biol. 32:648–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li L, Ma Y, Xu Y and Maerkeya K: TIM-3
expression identifies a distinctive PD-1+follicular helper T cell
subset, with reduced interleukin 21 production and B cell help
function in ovarian cancer patients. Int Immunopharmacol.
57:139–146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kuchroo VK, Umetsu DT, DeKruyff RH and
Freeman GJ: The TIM gene family: Emerging roles in immunity and
disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ovarian tumor tissue analysis (OTTA)
consortium, ; Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W,
Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, et al:
Dose-response association of CD8+ tumor-infiltrating lymphocytes
and survival time in high-grade serous ovarian cancer. JAMA Oncol.
3:e1732902017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kalachand RD, Ruscito I, Dimitrova D,
Panici PB, Sehouli J, Olek S, Braicu EI, Lu L, Katsaros D, Yu H, et
al: Clinical characteristics and survival outcomes in
BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled
analysis of data for 1,278 patients across five studies. J Clin
Oncol 33:. (Suppl 15):S55262018.
|
